Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 14/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.69 |
| ▸ | KIT | P10721 | 3/20 | 0.69 |
| ▸ | FLT3 | P36888 | 3/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599422 | 0.91 | PDGFRB (0.63) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL4971003 | 0.88 | PDGFRB (0.71) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL4966763 | 0.88 | ENPP1 (0.71) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL4969179 | 0.86 | PDGFRB (0.69) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL14599425 | 0.85 | PDGFRB (0.73) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL14599423 | 0.85 | PDGFRB (0.59) | PDGFRBPDGFRAKITFLT3BCHE | |
| SCHEMBL4975720 | 0.85 | PDGFRB (0.56) | PDGFRBPDGFRAKITFLT3ENPP1 | |
| SCHEMBL5072193 | 0.85 | PDGFRB (0.58) | PDGFRBPDGFRAKITFLT3 | |
| SCHEMBL4969207 | 0.84 | PDGFRB (0.66) | PDGFRBPDGFRAKITFLT3 | |
| SCHEMBL4972356 | 0.84 | PDGFRB (0.66) | PDGFRBPDGFRAKITFLT3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242838-A | Synergistic modulation of FLT3 kinase using aminoquinoline and aminoquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | PDGFRB 284/4885PDGFRA 460/4885KIT 197/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | PDGFRB 51/4885PDGFRA 74/4885KIT 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.